Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. (BUCiL)
Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Listed as NCT01705184, this PHASE2 trial focuses on Non-small Cell Lung Cancer Metastatic and Nonsquamous Nonsmall Cell Neoplasm of Lung and remains completed. Sponsored by Intergroupe Francophone de Cancerologie Thoracique, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intergroupe Francophone de Cancerologie Thoracique
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Avignon, France , Caen, France , Chauny, France , Le Mans, France , Marseille, France , Mulhouse, France , Nantes, France , Paris, France , Pierre-Bénite, France , Rennes, France and 1 more location